Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

Background Phase III trials demonstrated effectiveness of tofacitinib, an oral Janus kinase inhibitor, to induce and maintain remission in patients with moderate-to-severe active ulcerative colitis (UC). Aims We report the real-world effectiveness and safety of tofacitinib in patients with UC in France. Methods From February 2017 to December 2018, we performed a national French cohort study, which included all consecutive patients with an active...